Literature DB >> 17320860

Effect of PPARalpha activation of macrophages on the secretion of inflammatory cytokines in cultured adipocytes.

Kentaro Murakami1, Hideaki Bujo, Hiroyuki Unoki, Yasushi Saito.   

Abstract

The relationship between adipocytes and infiltrated macrophages in fat tissue is important for the pathogenesis of insulin resistance through the activation of cytokines. Peroxisome proliferator-activated receptors (PPARs) play a role in the regulation of cytokine secretion in these cells. We studied the effect of the PPARalpha activation of macrophages on the modulation of the tumor necrosis factor alpha (TNFalpha) expression in adipocytes using a cell culture system. A conditioned medium of lipopolysaccharide (LPS)-stimulated RAW264.7 cells, a macrophage cell line, induced the level of TNFalpha mRNA in 3T3-L1 adipocytes. This effect was inhibited by the addition of neutralizing antibody against interleukin 6 (IL-6) in the conditioned medium or the preincubation of RAW264.7 cells with a specific PPARalpha agonist, K-111 (2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid). K-111 reduced both the IL-6 production and mRNA expression in RAW264.7 cells, and its effect was stronger than that of rosiglitazone, a PPARgamma agonist. The activation of the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway and nuclear factor kappa B (NF-kappaB) subunits of p65 was significantly inhibited by K-111. The blocking of IL-6 production through the SAPK/JNK pathway or by transfection with siRNA specific for IL-6 abolished the inhibitory effect of K-111 on the TNFalpha expression in the 3T3-L1 adipocytes. As a result, the IL-6 produced by RAW264.7 cells is an inducer of TNFalpha expression in 3T3-L1 adipocytes, and the IL-6 secretion is inhibited by the activation of PPARalpha. The PPARalpha activators may suppress the pathogenetical secretion of TNFalpha in the adipocytes through the functional modulation of the infiltrated macrophages.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17320860     DOI: 10.1016/j.ejphar.2006.12.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  A Novel Peroxisome Proliferator-activated Receptor (PPAR)α Agonist and PPARγ Antagonist, Z-551, Ameliorates High-fat Diet-induced Obesity and Metabolic Disorders in Mice.

Authors:  Yoshihiro Shiomi; Toshimasa Yamauchi; Masato Iwabu; Miki Okada-Iwabu; Ryo Nakayama; Yuki Orikawa; Yoshichika Yoshioka; Koichiro Tanaka; Kohjiro Ueki; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2015-04-23       Impact factor: 5.157

2.  Establishment of the insulin resistance induced by inflammatory response in 3T3-L1 preadipocytes cell line.

Authors:  Yuan Zhou; Bao-lin Liu; Kang Liu; Ning Tang; Jue Huang; Yuan An; Lin Li
Journal:  Inflammation       Date:  2008-10       Impact factor: 4.092

3.  Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6.

Authors:  Elizabeth J Hennessy; Frederick J Sheedy; David Santamaria; Mariano Barbacid; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

4.  Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression.

Authors:  Song Han; Guiyun Wang; Xiang Qi; Ella W Englander; George H Greeley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-25       Impact factor: 4.052

Review 5.  PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

Authors:  Sean R Pyper; Navin Viswakarma; Songtao Yu; Janardan K Reddy
Journal:  Nucl Recept Signal       Date:  2010-04-16

6.  The PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.

Authors:  Rashmi Kumari; Lisa B Willing; Shyama D Patel; J Kyle Krady; William J Zavadoski; E Michael Gibbs; Susan J Vannucci; Ian A Simpson
Journal:  J Cereb Blood Flow Metab       Date:  2009-10-28       Impact factor: 6.200

7.  Metabolic profiling of PPARalpha-/- mice reveals defects in carnitine and amino acid homeostasis that are partially reversed by oral carnitine supplementation.

Authors:  Liza Makowski; Robert C Noland; Timothy R Koves; Weibing Xing; Olga R Ilkayeva; Michael J Muehlbauer; Robert D Stevens; Deborah M Muoio
Journal:  FASEB J       Date:  2008-10-22       Impact factor: 5.191

8.  Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain.

Authors:  D R Sagar; D A Kendall; V Chapman
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

9.  A newly identified CG301269 improves lipid and glucose metabolism without body weight gain through activation of peroxisome proliferator-activated receptor alpha and gamma.

Authors:  Hyun Woo Jeong; Joo-Won Lee; Woo Sik Kim; Sung Sik Choe; Kyung-Hee Kim; Ho Seon Park; Hyun Jung Shin; Gha Young Lee; Dongkyu Shin; Hanjae Lee; Jun Hee Lee; Eun Bok Choi; Hyeon Kyu Lee; Heekyoung Chung; Seung Bum Park; Kyong Soo Park; Hyo-Soo Kim; Seonggu Ro; Jae Bum Kim
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

10.  Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation.

Authors:  Maja Grabacka; Krzysztof Reiss
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.